The GLP-1 content landscape has a gap problem: nearly everything written focuses on starting semaglutide or tirzepatide and losing weight. Almost nothing covers what actually comes next — the maintenance phase most patients will spend years in.
Here's what the data shows and what the practical experience looks like.
Why Maintenance Is Different
Weight loss and weight maintenance are physiologically different states. During active loss, you're in a caloric deficit, leveraging maximum GLP-1 suppression to drive intake down. During maintenance, you're trying to hold a new set point with a metabolic system that still "wants" its old weight.
The challenge: GLP-1 receptors don't stop mattering once you hit goal. Obesity is a chronic metabolic disease, and GLP-1 medications treat the underlying physiology — not just the symptom of excess weight.
The STEP 4 trial made this clear. Patients who reached goal weight and discontinued semaglutide regained two-thirds of lost weight within a year. This isn't a willpower failure — it's the underlying condition reasserting itself.
What Maintenance Dosing Actually Looks Like
Most patients don't need the same dose for maintenance that they needed for active loss. The goal in maintenance is finding the minimum effective dose that holds your set point — your "maintenance minimum."
For semaglutide: The clinical approach is gradual titration down from your peak loss dose. Many patients find they can maintain at 1.0mg or 1.7mg instead of the 2.4mg they needed for active loss. Some do fine at 0.5mg. Finding your minimum is a process of stepping down slowly (4-8 weeks per step) and monitoring weight.
For tirzepatide: Similar approach. Peak doses of 10mg-15mg during active loss sometimes reduce to 5mg-7.5mg for maintenance without regain. Individual variation is significant.
What "stepping down" means clinically: The physician reduces dose by one step, you hold for 4-6 weeks and monitor weight. If stable, continue. If gaining 3-5+ pounds, step back up. It's an iterative process — not a one-time decision.
The Case for Long-Term Use
The evidence increasingly supports viewing GLP-1 therapy as chronic disease management rather than a weight loss "course." Here's why:
Metabolic effects extend beyond weight. Semaglutide's cardiovascular benefits in the SELECT trial — a 20% reduction in major cardiac events — occurred in patients who were already at their weight target. The cardiometabolic effects are partially independent of the weight loss itself.
Set point defense doesn't stop. The metabolic adaptations that drove weight regain existed before GLP-1 therapy and continue after it. For most patients with obesity, the underlying mechanism doesn't "reset."
Quality of life data is strong. Patients on long-term GLP-1 consistently report sustained reductions in food noise, improved relationship with eating, and better energy — not just lower weight.
What Stopping Looks Like
If you choose to discontinue — whether for cost, side effects, or preference — understanding what to expect changes the experience.
Stopping isn't dangerous. But it is informative. Most patients experience increased appetite return within 2-4 weeks, and weight trajectory begins reversing within 1-3 months. The speed varies by individual metabolic factors.
The most successful long-term discontinuations share common factors: - Sustained behavioral change during the treatment window (new food patterns, exercise habits) - Gradual taper rather than abrupt stop - Active monitoring and willingness to restart if needed - Realistic expectations about ongoing biological pull toward prior weight
The Financial Reality
Long-term GLP-1 therapy at branded prices ($900-1,300/month) is prohibitively expensive for most patients. This is a real barrier to the "chronic disease management" model that the clinical evidence supports.
Compounded semaglutide and tirzepatide at $100-300/month changes the math entirely. For patients who've reached goal and need maintenance dosing, compounded options at lower doses are often the only sustainable path.
The maintenance dose advantage: lower doses generally mean lower cost per dose, making long-term maintenance more economically viable than the active loss phase.
Finding Your Minimum Effective Dose
Working with a physician on dose titration during maintenance isn't optional — it's how you find the right long-term protocol. The minimum effective dose is different for every person and can shift over time.
At Marrow, patients transitioning to maintenance get physician-guided titration with regular check-ins to find their individual set point. The goal isn't the maximum dose forever — it's the right dose for your biology, for as long as it makes sense for you.
Frequently Asked Questions
Can you reduce your GLP-1 dose after reaching goal weight?
Yes — and this is typically recommended. Most patients don't need the same dose for maintenance that drove active weight loss. The process involves gradual step-down with monitoring, finding the minimum dose that holds your target weight. This varies significantly by individual. Your physician should guide this titration rather than making abrupt changes.
Will I gain weight if I stop GLP-1 medications?
Most patients do regain significant weight after stopping GLP-1 medications. The STEP 4 trial found patients regained about two-thirds of lost weight within a year of discontinuing semaglutide. This reflects the chronic nature of obesity — the underlying metabolic condition doesn't change when medication stops. Some patients successfully maintain with strong behavioral changes established during treatment, but this is less common than the clinical evidence would suggest is ideal.
How long do you have to stay on GLP-1 for weight maintenance?
The clinical evidence supports long-term or indefinite use for most patients with obesity, similar to how you'd treat other chronic conditions like hypertension or diabetes. For patients who achieved goal weight, the question isn't whether to stop — it's whether the benefits justify continuing. For many, they do, especially considering cardiovascular and metabolic benefits beyond weight.
What is the minimum effective dose of semaglutide for maintenance?
There's no universal answer — minimum effective maintenance doses range from 0.5mg to 2.4mg weekly depending on individual metabolism, starting weight, and treatment goals. Finding your minimum requires physician-supervised titration: reducing dose gradually (4-8 weeks per step) and monitoring weight. If stable after 6-8 weeks at lower dose, continue stepping down. If gaining, step back up.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
